Feedback PLC Presentation at RSNA 2017
22 November 2017 - 8:01AM
RNS Non-Regulatory
TIDMFDBK
Feedback PLC
22 November 2017
Presentation at RSNA 2017
Cambridge, UK - 22 November 2017: Feedback plc ("Feedback" or
the "Company") (AIM: FDBK), the specialist medical imaging
technology company, announces that Dr Balaji Ganeshan will be
presenting at the 103(rd) Scientific Assembly and Annual Meeting of
the Radiological Society of North America ("RSNA 2017") taking
place from 26 November to 1 December 2017 in Chicago (IL), USA.
The details for the oral presentation on the study undertaken at
the Institute of Nuclear Medicine, University College London, UK
are as follows:
Date and session time: Wednesday 29 November at 15:00 - 16:00
CST
Title: Texture Analysis of 68Ga-DOTATATE Positron Emission
Tomography and Computed Tomography Images as a Prognostic Biomarker
in Adults with Neuro-Endocrine Cancers Treated with
177Lu-DOTATATE
Abstract number: SSM13-06
Session: Molecular Imaging (Analysis and Quantification)
Room: S504C
Presenter: Balaji Ganeshan, PhD
Two additional papers co-authored by Dr Balaji Ganeshan will be
presented at RSNA 2017; one by Seoul National University and
University College London focused on liver cancer (abstract
SSK07-05), and one by Cambridge University, the University of Rome
and University College London focused on ischemic stroke (abstract
SSQ15-02). Overall, RSNA 2017 is expected to include at least 18
scientific paper presentations featuring TexRAD(R) Computed
Tomography Texture Analysis (CTTA) and Magnetic Resonance Texture
Analysis (MRTA), many of which have won awards in this year's RSNA
categories. Further information can be found at
https://rsna2017.rsna.org/program.
Dr Balaji Ganeshan, Director of New Business at Feedback plc,
said: "RSNA is the premier global event for radiologists and the
increasing focus on our TexRAD(R) technology is encouraging. As
seen in previous years, our renowned customers will highlight
multiple TexRAD(R) presentations across various disease
indications, further emphasising the significance of our technology
across the healthcare industry. We look forward to discussing
TexRAD(R) with this year's RSNA delegates."
TexRAD(R) is the Company's patented quantitative image texture
analysis technology for diagnostic radiological scans. The
technology has the potential to assist clinicians in diagnosis,
prognosis and treatment of patients with cancer, or other disease
indications, and is currently installed in over 40 of the world's
leading research institutions across Europe, North America, Asia
and Australasia. By analysing the texture features in computerised
tomography (CT) scans, magnetic resonance images (MRI) and positron
emission tomography scans (PET/CT), TexRAD(R) 's quantitative
imaging capabilities provide clinicians with additional, visually
imperceptible information to make better decisions in order to
improve patient outcomes.
TexRAD(R) research to date has shown great potential in many
different oncological and non-oncological sites. In particular, the
papers being presented at RSNA 2017 focus on liver, pancreatic,
kidney, cervical, oral, genitourinary, head & neck, thyroid,
neuroendocrine and endometrial cancers, as well as gastrointestinal
stromal tumours, gliomas, thymic-epithelial neoplasms and
carotid-plaques. On 20 November 2017, Feedback announced the CE
marked release of TexRAD(R) Lung, a "software only" Class 1 medical
device, to help advance lung cancer diagnosis. Further information
on the TexRAD(R) technology can be found at www.texrad.com.
- Ends -
Notes to editors
About Feedback plc
Feedback plc is a specialist medical imaging technology company.
It develops software and systems that provide innovative techniques
and improved workflows for practitioners involved in medical
research and treating patients. TexRAD(R) , the Company's patented
quantitative image texture analysis technology, has the potential
to assist clinicians in diagnosis, prognosis and treatment of
patients with cancer and is currently installed in over 40 of the
world's leading research institutions across Europe, North America,
Asia and Australasia. The Cadran platform provides a suite of
medical imaging tools for decision support. The Cadran range
includes the picture archiving communication system (PACS) to
provide decision support for scan analysis, diagnostic workstations
which provide secure remote access to view scans on demand, and
products to securely share and transport patient data. Visit
www.fbk.com.
For further information, please contact:
Feedback plc Tel: 01954 718072
Dr Alastair Riddell, Chairman hello@fbk.com
Lara Mott, Investor Relations
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFMMZMNMDGNZM
(END) Dow Jones Newswires
November 22, 2017 02:01 ET (07:01 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024